Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Barclay, M.L.; Kirkpatrick, C.M.J.; Begg, E.J.; Kirkpatrick, C M
February 1999
Clinical Pharmacokinetics;1999, Vol. 36 Issue 2, p89
Academic Journal
journal article
After 50 years of clinical experience with the aminoglycoside agents, there is continuing debate over the most appropriate administration regimen for these drugs. In recent years, once daily administration has been used increasingly, in the hope of both improving efficacy and reducing toxicity. At least 30 controlled clinical trials have compared once versus conventional multiple daily administration. Efficacy was assessed in some, but not all, studies using clinical and/or bacteriological cure. Toxicity was generally determined using rather nonsensitive end-points such as measurement of serum creatinine for nephrotoxicity and clinically detectable hearing loss for ototoxicity. The results of individual clinical trials and subsequent meta-analyses have been variable. However, 5 of 9 meta-analyses found clinical efficacy to be significantly better with once daily administration, and in 3 of the 9 there were significantly less nephrotoxicity with once daily administration. The results were not significant for ototoxicity in any of the meta-analyses. There is debate about how therapeutic drug monitoring should be performed, and whether it is still required with once daily administration. Previous experience with the aminoglycosides, especially in patients with impaired drug clearance caused by renal impairment, suggests that monitoring is still prudent. Results from the once daily administration trials appear to support this. Various methods of monitoring and dose adjustment have been proposed. The most common is to measure a 24-hour trough concentration and to adjust the dose to maintain the trough concentration below a value of 2, 1 or 0.5 mg/L. However, this method allows for greater total aminoglycoside exposure than has been permitted with conventional dosages, increasing the likelihood of toxicity in patients with impaired aminoglycoside clearance. Other methods measure drug concentrations at a time-point or points within the dose interval (when the concentration is still measurable), and adjust the dose according to concentration-time curve nomograms or to a target area under the concentration-time curve. This allows the use of higher doses in those with high drug clearance. Furthermore, in patients with impaired clearance, drug exposure is limited to the same extent as, or less than, that with conventional multiple daily administration. To date no controlled trials have compared methods of dose-individualisation. In summary, in addition to a slight overall improvement in efficacy, once daily administration has resulted in a small reduction in nephrotoxicity. In the studies using more sensitive measures of toxicity, the differences in toxicity were greater, strengthening the case for once daily administration. Therapeutic drug monitoring is probably required with once daily administration. Methods which use mid-dosage interval concentrations to gauge drug exposure would seem to be preferable over trough concentration measurement.


Related Articles

  • Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p29 

    Presents results of a study which compares standard aminoglycoside administration with once-a-day dosing among 1625 immunocompetent, infected adults. Bacteriologic cure rates; Decreased nephrotoxicity among patients given a once-a-day therapy.

  • Single or multiple daily doses of aminoglycosides: A meta-analysis. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p29 

    Presents results of a study which compares single with multiple daily doses of aminoglycosides and which involved children and neutropenic cancer patients, most of whom were without preexisting renal disease.

  • A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily... Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p30 

    Presents meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. Absence of significant difference in bacteriologic efficacy or nephrotoxicity between the two dosing schedules; Ototoxicity rates.

  • Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p30 

    Presents a meta-analysis of the effectiveness and safety of once-daily dosage of aminoglycosides. Inclusion of studies in which aminoglycosides were administered for prophylaxis; Decreased nephrotoxicity; Comments on the meta-analysis include those on the duration of treatment and the method...

  • Once-daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p31 

    Presents results of a study in which once-daily aminoglycoside dosing for adult patients were conducted. Therapeutic drug monitoring; Nephrotoxicity; Comment on the absence of rationale for checking peak drug levels.

  • New dosing regimens for aminoglycoside antibiotics. Levison, Matthew E.; Levison, M E // Annals of Internal Medicine;10/15/92, Vol. 117 Issue 8, p693 

    Explains the rationale underlying the novel proposal of a single daily dosing of aminoglycosides. Problems with aminoglycosides; Information on the clinical efficacy of aminoglycosides; Factors which allows the ability to prolong the dosing interval without loss of efficacy of aminoglycosides.

  • High-dose amikacin for achieving serum target levels in critically ill elderly patients. Sadeghi, Kourosh; Hamishehkar, Hadi; Najmeddin, Farhad; Ahmadi, Arezoo; Hazrati, Ebrahim; Honarmand, Hooshyar; Mojtahedzadeh, Mojtaba // Infection & Drug Resistance;Feb2018, Vol. 11, p223 

    Introduction: To achieve target concentrations, the application of higher-than-standard doses of amikacin is proposed for the treatment of sepsis due to an increase in volume of distribution and clearance, but little data are available on aminoglycoside administration in critically ill elderly...

  • Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Tod, M.M.; Padoin, C.; Petitjean, O. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 11, p803 

    Measurements of aminoglycoside concentration in serum are used to individualise dosage regimens (dose per administration and/or administration interval) with the goal of attaining the desired therapeutic range as quickly as possible. Therapeutic range is defined in terms of peak concentration...

  • Rituximab: Colonic perforation: case report.  // Reactions Weekly;7/13/2019, Vol. 1761 Issue 1, p329 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics